In conclusion, EA displays marked in vitro and in vivo antitumor activity against human bladder cancer, as a result of different effects: inhibition of tumor cell proliferation; migration and invasion of the extracellular matrix in response to VEGF-A; down-modulation of PD-L1; and decreased tumor-associated angiogenesis. This evidence concerns the gene VEGFA and neoplasm.